爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

b. braun melsungen ag - joodpovidoon - nahalahus - 75mg 1g 100ml 1tk; 75mg 1g 1000ml 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

sopharma ad - joodpovidoon - salv - 100mg 1g 20g 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

b. braun melsungen ag - joodpovidoon - salv - 100mg 1g 20g 1tk; 100mg 1g 100g 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

riga pharmaceutical plant - jood - nahalahus - 5% 20ml 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

cid lines - jood - nisakastutus-/nisasprei lahus - 3mg 1g 25000ml 1tk; 3mg 1g 20000ml 1tk; 3mg 1g 60000ml 1tk; 3mg 1g 200000ml 1tk; 3mg 1g 1000ml 1tk; 3mg 1g 10000ml 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

cid lines - jood - nisakastutuslahus - 3mg 1g 20000ml 1tk; 3mg 1g 5000ml 1tk; 3mg 1g 10000ml 1tk; 3mg 1g 60000ml 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

valentis uab - jood - nahalahus - 50mg 1ml 10ml 1tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

cp-pharma handelsgesellschaft mbh - joodpovidoon - nahasprei, lahus - 2,5% 250ml 1tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).